Professor Thomas Helleday at Karolinska Institutet and Biovica in research collaboration to evaluate new promising cancer treatments

The laboratory headed by Thomas Helleday at Karolinska Institutet, (Stockholm) and Biovica (Uppsala) have entered a research collaboration to improve evaluation and development of new, promising cancer therapies.
The aim of the collaboration project is to assess whether information gathered with Biovicas DiviTum™ assay has the potential to provide early evidence of efficacy regarding the development of two promising cancer treatments. The Helleday Laboratory develops two promising drug candidates targeting DNA damage repair functions. Strategy is to exploit the high level of DNA damage in cancer cells and prevent the repair of these lesions.

MTH1 inhibitors, targeting DNA repair can generate toxic DNA damage selectively in cancer cells. The impact of these compounds on cell cycle activity is evaluated with DiviTum™, an assay that measures a fundamental enzyme regulating cell proliferation. The collaboration will address whether the enzyme levels measured with DiviTum™ can be used to predict and evaluate efficacy as well as provide early evidence of a potential responder biomarker for any of these types of treatments. This knowledge has the potential to be translated to a clinical setting and help to improve patient selection and monitoring.

Thomas Helleday, (Professor) at the Karolinska Institutet says: “Taking a novel compound into clinic requires companion biomarkers. To have this opportunity to investigate whether Biovica’s DiviTum™ assay can be used as a possible diagnostic tool for our novel anticancers treatment is something we are looking forward to do.

Anders Rylander, CEO at Biovica states: “We look forward to collaborate with the reputable Karolinska Institutet and bring benefit to their development program. With our DiviTum technology we want to bring value to drug developers by providing them with a tool for better evaluation and more informed decisions earlier in the development process. By doing this we hope to accelerate the development of promising drugs benefiting cancer patients and assist oncologists in their everyday decisions.”

ABOUT THE THOMAS HELLEDAY LABORATORY AT KAROLINSKA INSTITUTET

The vision of Helleday Laboratory, Karolinska Institutet, is to translate the findings from our basic research programmes on DNA repair and survival mechanisms within cancer cells, into identification of novel anti-cancer targets and development of anti-cancer drugs with minimal side-effects.  Today we have taken discovery projects into pre-clinical phase and are presently planning for initiating clinical trials during next year.
The laboratory is located at SciLifeLab and consists of appr 70 researchers, PhD students and postdocs within medical chemistry, biochemistry, cell biology and pharmacology. For a more comprehensive description of our different projects and an overview of our group, please visit our website www.helleday.org. The Helleday Laboratory is known for its research initiatives and progress in finding new ways to treat cancer from a biological perspective with high academic integrity.

ABOUT BIOVICA AND DIVITUM™

Biovica is a bio-diagnostic company focused on providing improved diagnostics, predictive data and monitoring of cancer patient under treatment. Biovica has developed DiviTum™, a highly sensitive assay for measuring cell proliferation. Since one of the most fundamental characteristics of cancer is uncontrolled and increased cell growth, DiviTum™ enables valuable prediction capability and monitoring of compounds regulating cell proliferation and the cell cycle. Biovica is ISO 13485 certified for Quality Management Systems and DiviTum™ is CE labelled and MPA registered.

CONTACT

Anders Rylander, CEO

Direct +46 (0) 18 44 44 835
E-mail anders.rylander@biovica.com

2017-01-03T10:51:07+00:00 January 29th, 2016 11:00|Press Release|